Trials / Completed
CompletedNCT04963738
A Study of JNJ-73763989 in Adult Participants With Renal Impairment
An Open-label, Single-dose, Parallel-group Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of JNJ-73763989 in Adult Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the pharmacokinetics (PK) of a single subcutaneous (SC) dose of JNJ-73763989 in adult participants with renal impairment compared with healthy participants with normal renal function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-73763989 | JNJ-73763989 will be administered as a single SC injection. |
Timeline
- Start date
- 2021-09-22
- Primary completion
- 2022-10-17
- Completion
- 2022-10-17
- First posted
- 2021-07-15
- Last updated
- 2023-11-09
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT04963738. Inclusion in this directory is not an endorsement.